364 related articles for article (PubMed ID: 22677550)
21. A novel CFHR5 mutation associated with C3 glomerulonephritis in a Turkish girl.
Besbas N; Gulhan B; Gucer S; Korkmaz E; Ozaltin F
J Nephrol; 2014 Aug; 27(4):457-60. PubMed ID: 24536001
[TBL] [Abstract][Full Text] [Related]
22. Apolipoprotein E is enriched in dense deposits and is a marker for dense deposit disease in C3 glomerulopathy.
Madden B; Singh RD; Haas M; Palma LMP; Sharma A; Vargas MJ; Gross L; Negron V; Nate T; Charlesworth MC; Theis JD; Nasr SH; Nath KA; Fervenza FC; Sethi S
Kidney Int; 2024 May; 105(5):1077-1087. PubMed ID: 38447879
[TBL] [Abstract][Full Text] [Related]
23. Alternative pathway dysfunction in kidney disease: a case report and review of dense deposit disease and C3 glomerulopathy.
Hawfield A; Iskandar SS; Smith RJ
Am J Kidney Dis; 2013 May; 61(5):828-31. PubMed ID: 23391537
[TBL] [Abstract][Full Text] [Related]
24. C3 glomerulonephritis and systemic lupus erythematosus: A report of a patient treated with eculizumab and review of the literature.
Fernandez-Ruiz R; Blank RB; Wu M; Belmont HM
Lupus; 2021 Sep; 30(10):1671-1678. PubMed ID: 34192954
[TBL] [Abstract][Full Text] [Related]
25. C3 Glomerulopathy and post-infectious glomerulonephritis define a disease spectrum.
Al-Ghaithi B; Chanchlani R; Riedl M; Thorner P; Licht C
Pediatr Nephrol; 2016 Nov; 31(11):2079-86. PubMed ID: 27008643
[TBL] [Abstract][Full Text] [Related]
26. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial.
Ruggenenti P; Daina E; Gennarini A; Carrara C; Gamba S; Noris M; Rubis N; Peraro F; Gaspari F; Pasini A; Rigotti A; Lerchner RM; Santoro D; Pisani A; Pasi A; Remuzzi G;
Am J Kidney Dis; 2019 Aug; 74(2):224-238. PubMed ID: 30929851
[TBL] [Abstract][Full Text] [Related]
27. C3 glomerulopathy: A new complement-based entity.
de Lorenzo A; Tallón S; Hernández-Sevillano B; de Arriba G
Rev Clin Esp (Barc); 2014; 214(5):266-74. PubMed ID: 24576419
[TBL] [Abstract][Full Text] [Related]
28. A Narrative Review on C3 Glomerulopathy: A Rare Renal Disease.
Schena FP; Esposito P; Rossini M
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31947692
[TBL] [Abstract][Full Text] [Related]
29. Proliferative C4 Dense Deposit Disease, Acute Thrombotic Microangiopathy, a Monoclonal Gammopathy, and Acute Kidney Failure.
Ali A; Schlanger L; Nasr SH; Sethi S; Gorbatkin SM
Am J Kidney Dis; 2016 Mar; 67(3):479-82. PubMed ID: 26704376
[TBL] [Abstract][Full Text] [Related]
30. Rituximab fails where eculizumab restores renal function in C3nef-related DDD.
Rousset-Rouvière C; Cailliez M; Garaix F; Bruno D; Laurent D; Tsimaratos M
Pediatr Nephrol; 2014 Jun; 29(6):1107-11. PubMed ID: 24408225
[TBL] [Abstract][Full Text] [Related]
31. Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS).
Sethi S; Fervenza FC
Semin Thromb Hemost; 2014 Jun; 40(4):416-21. PubMed ID: 24799306
[TBL] [Abstract][Full Text] [Related]
32. Eculizumab in Pediatric Dense Deposit Disease.
Oosterveld MJ; Garrelfs MR; Hoppe B; Florquin S; Roelofs JJ; van den Heuvel LP; Amann K; Davin JC; Bouts AH; Schriemer PJ; Groothoff JW
Clin J Am Soc Nephrol; 2015 Oct; 10(10):1773-82. PubMed ID: 26316621
[TBL] [Abstract][Full Text] [Related]
33. Validation of a Histologic Scoring Index for C3 Glomerulopathy.
Caravaca-Fontán F; Trujillo H; Alonso M; Díaz-Encarnación M; Cabello V; Ariceta G; Quintana LF; Marco H; Barros X; Ramos N; Rodríguez-Mendiola N; Cruz S; Fernández-Juárez G; Rodríguez E; de la Cerda F; Pérez de José A; López I; Fernández L; Pérez Gómez V; Ávila A; Bravo L; Lumbreras J; Allende N; Sanchez de la Nieta MD; Olea T; Melgosa M; Huerta A; Miquel R; Mon C; Fraga G; de Lorenzo A; Draibe J; González F; Shabaka A; Illescas ML; Calvo C; Oviedo V; Da Silva I; Goicoechea de Jorge E; Caravaca F; Praga M;
Am J Kidney Dis; 2021 May; 77(5):684-695.e1. PubMed ID: 33359150
[TBL] [Abstract][Full Text] [Related]
34. Electron-dense deposit in renal transplant patients on eculizumab may be drug-derived.
Brealey JK; Cassidy J
Ultrastruct Pathol; 2016; 40(1):2-6. PubMed ID: 26512451
[TBL] [Abstract][Full Text] [Related]
35. C4d as a Diagnostic Tool in Proliferative GN.
Sethi S; Nasr SH; De Vriese AS; Fervenza FC
J Am Soc Nephrol; 2015 Nov; 26(11):2852-9. PubMed ID: 25991041
[TBL] [Abstract][Full Text] [Related]
36. Anti-complement therapy for glomerular diseases.
Bomback AS
Adv Chronic Kidney Dis; 2014 Mar; 21(2):152-8. PubMed ID: 24602464
[TBL] [Abstract][Full Text] [Related]
37. Proliferative Glomerulonephritis With Fibrils, Monoclonal κ Light Chain, and C3 Deposits.
Steinberg AG; Fox LC; Bender S; Batrouney A; Juneja S; Sirac C; Touchard G; Blombery P; Finlay MJ; Bridoux F; Barbour TD
Am J Kidney Dis; 2021 Sep; 78(3):459-463. PubMed ID: 33774080
[TBL] [Abstract][Full Text] [Related]
38. Histopathology of MPGN and C3 glomerulopathies.
Cook HT; Pickering MC
Nat Rev Nephrol; 2015 Jan; 11(1):14-22. PubMed ID: 25447133
[TBL] [Abstract][Full Text] [Related]
39. Myeloperoxidase immunohistochemical staining can identify glomerular endothelial cell injury in dense deposit disease.
Blatt NB; Kumar T; Wickman LT; Kanaan HD; Chang A; Zhang PL
Pediatr Nephrol; 2021 Dec; 36(12):4003-4007. PubMed ID: 34522991
[TBL] [Abstract][Full Text] [Related]
40. Toward a working definition of C3 glomerulopathy by immunofluorescence.
Hou J; Markowitz GS; Bomback AS; Appel GB; Herlitz LC; Barry Stokes M; D'Agati VD
Kidney Int; 2014 Feb; 85(2):450-6. PubMed ID: 24067430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
